Injected form of Leqembi appears effective at clearing amyloid, but with notable risks

New da­ta on an in­jectable form of Ei­sai’s Alzheimer’s drug Leqem­bi showed that it was more ef­fec­tive than an in­tra­venous ver­sion at clear­ing amy­loid, but al­so came with a high­er risk of brain-re­lat­ed side ef­fects known as ARIA.

The study, which was pre­sent­ed at the Clin­i­cal Tri­als on Alzheimer’s Dis­ease con­fer­ence in Boston, looked at pa­tients who got week­ly sub­cu­ta­neous in­jec­tions of Leqem­bi as an al­ter­na­tive to every-oth­er-week in­tra­venous in­fu­sions. The da­ta come from a six-month look at the study, and Ei­sai aims to sub­mit the for­mu­la­tion for ap­proval once it has a year’s worth of re­sults, by the end of March 2024, ac­cord­ing to Michael Irizarry, Ei­sai’s head of clin­i­cal neu­rol­o­gy re­search and deputy chief clin­i­cal of­fi­cer.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.